Arecor Therapeutics Advances Ultra-Concentrated Insulin AT278 Toward Phase II Trial in 2026
核心洞察
Arecor Therapeutics (搜索) is targeting a Phase II clinical trial for its ultra-concentrated insulin AT278 in the second half of 2026, following positive FDA feedback on its innovative study design.
The company is developing AT278 as a "best-in-class ultra-concentrated (500 U/mL) and ultra-rapid-acting insulin" through a 50:50 co-development partnership with Sequel Med Tech (搜索).
Arecor is also advancing an oral GLP-1 (搜索) platform aimed at improving bioavailability beyond the current less than 1% achieved by existing treatments like Rybelsus.
Arecor Therapeutics (搜索) PLC is positioning itself for a pivotal Phase II clinical trial of its ultra-concentrated insulin candidate AT278 in the second half of 2026, following successful regulatory discussions and strategic partnerships that could transform diabetes (搜索) treatment for patients with high insulin requirements.
Ultra-Concentrated Insulin Development
The Cambridge-based biopharmaceutical company is developing AT278 as what CEO Sarah Howell describes as a "new unique best-in-class ultra-concentrated (500 U/mL) and ultra-rapid-acting insulin for the treatment of diabetes (搜索)." The candidate is progressing through a 50:50 co-development partnership with Sequel Med Tech (搜索), established in September 2025 with both parties committing up to $1.3 million to support AT278's development in combination with Sequel's twiist automated insulin delivery system.
The Phase II trial will specifically target people with high daily insulin needs and builds on positive feedback from a successful Type C meeting with the US Food and Drug Administration, where Arecor received endorsement for its innovative clinical study design.
"The combination of AT278 with a device such as Sequel's twiist AID system addresses key unmet needs for people living with diabetes (搜索) and is a compelling proposition for this growing market," Howell stated.
Oral Peptide Platform Development
Beyond diabetes (搜索) treatment, Arecor is developing a platform for oral delivery of complex peptides, beginning with an improved formulation of glucagon-like peptide-1 (GLP-1 (搜索)) based on semaglutide. The company is addressing a significant bioavailability challenge, noting that existing oral GLP-1 treatments such as Rybelsus achieve "less than 1% oral bioavailability."
Arecor filed a European patent application in the final quarter of 2025 for novel compositions intended to improve absorption and is conducting non-clinical pharmacokinetic studies throughout 2026. Howell emphasized that the oral peptide platform "has a low resource burden but a large commercial upside opportunity" and could be highly translatable across multiple peptide therapeutics.
Financial Position and Strategic Focus
The company reported unaudited revenues of £3.1 million for 2025, down from £5.1 million in the prior year, reflecting the strategic discontinuation of Tetris Pharma operations. However, revenue from continuing activities rose slightly to £1.7 million.
Cash and cash equivalents increased significantly to £6.1 million from £3.2 million, attributed to favorable performance at Tetris prior to closure and a non-dilutive royalty financing deal with Ligand Pharmaceuticals worth up to $11 million, of which $7 million was received immediately. This financial position extends Arecor's operational runway into the first half of 2027.
Partnership Negotiations
Positive negotiations are currently underway regarding a broader co-development and commercialization partnership for the Phase II trial, which management has identified as a key objective for 2026. Both Arecor and Sequel Med Tech (搜索) share a vision of combining next-generation automated insulin delivery systems with next-generation insulin to improve patient outcomes and reduce disease management burden.
The strategic refocus during 2025 included the closure of Tetris Pharma and an emphasis on high-growth opportunities in diabetes (搜索) and peptide delivery, positioning the company for potential significant advances in cardiometabolic therapeutics.